Envestnet Portfolio Solutions Inc. Sells 28,957 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

Envestnet Portfolio Solutions Inc. decreased its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 64.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,060 shares of the pharmaceutical company's stock after selling 28,957 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in GSK were worth $622,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Parkside Financial Bank & Trust lifted its stake in shares of GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after buying an additional 818 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in GSK during the fourth quarter valued at approximately $39,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in GSK during the fourth quarter valued at approximately $40,000. Atala Financial Inc purchased a new stake in GSK during the fourth quarter valued at approximately $45,000. Finally, Whipplewood Advisors LLC bought a new position in shares of GSK in the fourth quarter worth approximately $46,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on GSK shares. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. BNP Paribas started coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target on the stock. Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, GSK presently has a consensus rating of "Hold" and a consensus target price of $37.38.

GSK Stock Up 0.8%

GSK stock opened at $38.59 on Friday. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $79.02 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 1.34 and a beta of 0.52. The firm has a 50 day moving average of $38.81 and a 200 day moving average of $36.91.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. GSK's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the firm posted $0.43 EPS. Sell-side analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a dividend yield of 4.37%. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. GSK's payout ratio is 87.11%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.